Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Rhea-AI Summary

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, has been featured in CEO/CFO Magazine. The article highlights the company's innovative gene therapies for cancer and diabetes. Ryan Confer, Genprex's President, CEO, and CFO, discussed:

- The company's gene therapy approaches in oncology and diabetes
- Recent updates to the Acclaim clinical trials in lung cancer
- New use of biomarker testing for the oncology program
- The popularity of GLP-1 agonists in diabetes treatment
- Potential partnerships and collaborations in gene therapy
- Plans to spin out the diabetes program into a wholly-owned subsidiary

Confer emphasized the importance of finding the right funding, partners, and collaborators to accelerate bringing innovative drugs to patients and creating value for stakeholders.

Positive

• Genprex's gene therapies for cancer and diabetes featured in CEO/CFO Magazine, potentially increasing visibility
• Company plans to spin out diabetes program into a wholly-owned subsidiary, potentially attracting focused partnerships and funding
• Implementation of biomarker testing for oncology program, potentially improving treatment efficacy

Negative

• None.

Company's CEO and CFO Highlights its Cutting-Edge Gene Therapy Programs

AUSTIN, Texas, Sept. 23, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's President, Chief Executive Officer and Chief Financial Officer, Ryan Confer, was featured in CEO/CFO Magazine discussing the Company's novel gene therapies for cancer and diabetes.

In this article, Confer describes the Company's gene therapy approaches in oncology and diabetes, recent updates to the Company's Acclaim clinical trials in lung cancer, and the Company's new use of biomarker testing for its oncology program. In diabetes, Confer comments on the popularity of GLP-1 agonists such as Novo Nordisk's Ozempic® and other new diabetic treatments, the future of potential partnerships and collaborations in gene therapy and for Genprex, and the medical and investment community's understanding of the potential value of gene therapy for diabetes.

Confer states in the CEO Magazine article:
"One thing we are excited about – as we just recently announced – is our plan to launch a spin out of our diabetes program into a wholly-owned subsidiary of Genprex. We believe this will allow us to explore potential partnerships with those entities solely focused on the diabetes program and find the right funding, partners, and collaborators that could drive these programs forward, which is important to us in terms of getting these innovative drugs to patients faster and to creating value for our stakeholders."

To read the article in its entirety, please visit the Media Coverage section on Genprex's website.

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
investors@genprex.com 

GNPX Media Contact
Kalyn Dabbs
media@genprex.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-featured-in-ceocfo-magazine-discussing-novel-gene-therapies-for-cancer-and-diabetes-302254771.html

SOURCE Genprex, Inc.

FAQ

What are Genprex's (GNPX) main focus areas for gene therapy?

Genprex (GNPX) is focused on developing gene therapies for cancer and diabetes.

What clinical trials is Genprex (GNPX) currently conducting?

Genprex (GNPX) is conducting the Acclaim clinical trials in lung cancer, as mentioned in the press release.

What new strategy has Genprex (GNPX) announced for its diabetes program?

Genprex (GNPX) plans to spin out its diabetes program into a wholly-owned subsidiary to explore potential partnerships and secure focused funding.

What new approach has Genprex (GNPX) implemented in its oncology program?

Genprex (GNPX) has implemented the use of biomarker testing in its oncology program.